MLAB
Mesa Laboratories, Inc. · Healthcare · Medical - Specialties
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 67 | 0 | 2.99M | $297.50M | +4 | −4 |
| Q1 2026 | 70 | 0 | 2.66M | $235.21M | +6 | −6 |
| Q4 2025 | 70 | +2 | 2.73M | $214.06M | +2 | — |
| Q3 2025 | 17 | +1 | 1.54M | $103.48M | +2 | −1 |
| Q2 2025 | 13 | +4 | 1.73M | $163.31M | +4 | — |
| Q1 2025 | 6 | -3 | 383.09K | $45.46M | — | −3 |
| Q4 2024 | 9 | +1 | 400.64K | $52.84M | +1 | — |
| Q3 2024 | 7 | 0 | 174.94K | $22.72M | +1 | −1 |
| Q2 2024 | 7 | — | 189.52K | $16.45M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 118.99K | — | $10.33M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 118.99K | — | $10.33M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 24.70K | — | $2.14M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 24.70K | — | $2.14M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 18.00K | — | $1.56M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 18.00K | — | $1.56M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 18.00K | — | $1.56M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Marshall Wace ✦ | 14.56K | — | $1.26M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Marshall Wace ✦ | 14.56K | — | $1.26M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 7.84K | — | $680,339 | 0.0% | n/c | 1 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 3.03K | — | $264,000 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Renaissance Technologies ✦ | 2.40K | — | $208,248 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 158 holders, 4.82M shares, $424.86M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer · President and CEO · 7.09K sh @ 112.80 · $800,090
Director · 900 sh @ 113.69 · $102,321
Open-market sales (S)
Director · 7.09K sh · $800,090
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology